4.3 Article

Epidemiology of multiple sclerosis in the Sultanate of Oman: A hospital based study

Journal

MULTIPLE SCLEROSIS AND RELATED DISORDERS
Volume 53, Issue -, Pages -

Publisher

ELSEVIER SCI LTD
DOI: 10.1016/j.msard.2021.103034

Keywords

Multiple sclerosis; Prevalence; Incidence; Oman; Arabs

Ask authors/readers for more resources

The prevalence of MS in the Omani population was estimated at 15.9 per 100,000, with a higher proportion of female patients than male patients. The majority of patients experienced their first clinical manifestation between the ages of 19-40.
Background: The prevalence of multiple sclerosis (MS) has been changing not only globally but also in individual countries. We aim to estimate the prevalence of MS in the Omani population over the period from 2006-2019 as well as the incidence between 2015-2018. Methods: This is a retrospective observational hospital-based study. All MS patients diagnosed, as per the revised McDonald criteria, over the period from June 2006 and until May 2019, had their information reviewed for age at disease onset, gender and year of diagnosis. We obtained the population of Oman from the national census data. Results: A total of 422 patients were diagnosed with MS during the study period and the population of Oman as per the 2019 census data was 2,652,199. The estimated crude prevalence was 15.9 (95% confidence interval: 14.4 - 17.5) per 100,000 and the female to male ratio was 2.17:1. The mean age at disease onset was 27.3 +/- 7.7 (range: 9 - 59) years in which 83% of the patients had the first clinical manifestation at the age of 19 - 40 years, while only 9% had a disease onset at <19 years. The annual incidence increased from 1.00 case per 100,000 in 2015 to 1.38 cases per 100,000 in 2018. Conclusion: The prevalence of MS in the Omani population is 15.9 per 100,000 placing Oman as a medium risk zone.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.3
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available